Development of Triiodothyronine Polymeric Nanoparticles for Targeted Delivery in the Cardioprotection against Ischemic Insult

Ischemic heart disease is the main cause of death globally. Cardioprotection is the process whereby mechanisms that reduce myocardial damage, and activate protective factors, contribute to the preservation of the heart. Targeting these processes could be a new strategy in the treatment of post-ische...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ozlem Ozen Karakus, Noureldien H. E. Darwish, Thangirala Sudha, Taher A. Salaheldin, Kazutoshi Fujioka, Peter C. Taylor Dickinson, Brian Weil, Shaker A. Mousa
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	thyroid hormone triiodothyronine Nano-T3 cardiac arrest ischemia phosphocreatine Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/0901cecc601a426b91c0339953814e0f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0901cecc601a426b91c0339953814e0f
record_format	dspace
spelling	oai:doaj.org-article:0901cecc601a426b91c0339953814e0f2021-11-25T16:51:10ZDevelopment of Triiodothyronine Polymeric Nanoparticles for Targeted Delivery in the Cardioprotection against Ischemic Insult10.3390/biomedicines91117132227-9059https://doaj.org/article/0901cecc601a426b91c0339953814e0f2021-11-01T00:00:00Zhttps://www.mdpi.com/2227-9059/9/11/1713https://doaj.org/toc/2227-9059Ischemic heart disease is the main cause of death globally. Cardioprotection is the process whereby mechanisms that reduce myocardial damage, and activate protective factors, contribute to the preservation of the heart. Targeting these processes could be a new strategy in the treatment of post-ischemic heart failure (HF). Triiodothyronine (T3) and thyroxine (T4), which have multiple effects on the heart, prevent myocardial damage. This study describes the formulation, and characterization, of chemically modified polymeric nanoparticles incorporating T3, to target the thyroid hormone receptors. Modified T3 was conjugated to polylactide-co-glycolide (PLGA) to facilitate T3 delivery and restrict its nuclear translocation. Modified T3 and PLGA-T3 was characterized with <sup>1</sup>H-NMR. The protective role of synthesized phosphocreatine (PCr) encapsulated PLGA-T3 nanoparticles (PLGA-T3/PCr NPs) and PLGA-T3 nanoparticles (PLGA-T3 NPs) in hypoxia-mediated cardiac cell insults was investigated. The results showed that PLGA-T3/PCr NPs represent a potentially new therapeutic agent for the control of tissue damage in cardiac ischemia and resuscitation.Ozlem Ozen KarakusNoureldien H. E. DarwishThangirala SudhaTaher A. SalaheldinKazutoshi FujiokaPeter C. Taylor DickinsonBrian WeilShaker A. MousaMDPI AGarticlethyroid hormonetriiodothyronineNano-T3cardiac arrestischemiaphosphocreatineBiology (General)QH301-705.5ENBiomedicines, Vol 9, Iss 1713, p 1713 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	thyroid hormone triiodothyronine Nano-T3 cardiac arrest ischemia phosphocreatine Biology (General) QH301-705.5
spellingShingle	thyroid hormone triiodothyronine Nano-T3 cardiac arrest ischemia phosphocreatine Biology (General) QH301-705.5 Ozlem Ozen Karakus Noureldien H. E. Darwish Thangirala Sudha Taher A. Salaheldin Kazutoshi Fujioka Peter C. Taylor Dickinson Brian Weil Shaker A. Mousa Development of Triiodothyronine Polymeric Nanoparticles for Targeted Delivery in the Cardioprotection against Ischemic Insult
description	Ischemic heart disease is the main cause of death globally. Cardioprotection is the process whereby mechanisms that reduce myocardial damage, and activate protective factors, contribute to the preservation of the heart. Targeting these processes could be a new strategy in the treatment of post-ischemic heart failure (HF). Triiodothyronine (T3) and thyroxine (T4), which have multiple effects on the heart, prevent myocardial damage. This study describes the formulation, and characterization, of chemically modified polymeric nanoparticles incorporating T3, to target the thyroid hormone receptors. Modified T3 was conjugated to polylactide-co-glycolide (PLGA) to facilitate T3 delivery and restrict its nuclear translocation. Modified T3 and PLGA-T3 was characterized with <sup>1</sup>H-NMR. The protective role of synthesized phosphocreatine (PCr) encapsulated PLGA-T3 nanoparticles (PLGA-T3/PCr NPs) and PLGA-T3 nanoparticles (PLGA-T3 NPs) in hypoxia-mediated cardiac cell insults was investigated. The results showed that PLGA-T3/PCr NPs represent a potentially new therapeutic agent for the control of tissue damage in cardiac ischemia and resuscitation.
format	article
author	Ozlem Ozen Karakus Noureldien H. E. Darwish Thangirala Sudha Taher A. Salaheldin Kazutoshi Fujioka Peter C. Taylor Dickinson Brian Weil Shaker A. Mousa
author_facet	Ozlem Ozen Karakus Noureldien H. E. Darwish Thangirala Sudha Taher A. Salaheldin Kazutoshi Fujioka Peter C. Taylor Dickinson Brian Weil Shaker A. Mousa
author_sort	Ozlem Ozen Karakus
title	Development of Triiodothyronine Polymeric Nanoparticles for Targeted Delivery in the Cardioprotection against Ischemic Insult
title_short	Development of Triiodothyronine Polymeric Nanoparticles for Targeted Delivery in the Cardioprotection against Ischemic Insult
title_full	Development of Triiodothyronine Polymeric Nanoparticles for Targeted Delivery in the Cardioprotection against Ischemic Insult
title_fullStr	Development of Triiodothyronine Polymeric Nanoparticles for Targeted Delivery in the Cardioprotection against Ischemic Insult
title_full_unstemmed	Development of Triiodothyronine Polymeric Nanoparticles for Targeted Delivery in the Cardioprotection against Ischemic Insult
title_sort	development of triiodothyronine polymeric nanoparticles for targeted delivery in the cardioprotection against ischemic insult
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/0901cecc601a426b91c0339953814e0f
work_keys_str_mv	AT ozlemozenkarakus developmentoftriiodothyroninepolymericnanoparticlesfortargeteddeliveryinthecardioprotectionagainstischemicinsult AT noureldienhedarwish developmentoftriiodothyroninepolymericnanoparticlesfortargeteddeliveryinthecardioprotectionagainstischemicinsult AT thangiralasudha developmentoftriiodothyroninepolymericnanoparticlesfortargeteddeliveryinthecardioprotectionagainstischemicinsult AT taherasalaheldin developmentoftriiodothyroninepolymericnanoparticlesfortargeteddeliveryinthecardioprotectionagainstischemicinsult AT kazutoshifujioka developmentoftriiodothyroninepolymericnanoparticlesfortargeteddeliveryinthecardioprotectionagainstischemicinsult AT peterctaylordickinson developmentoftriiodothyroninepolymericnanoparticlesfortargeteddeliveryinthecardioprotectionagainstischemicinsult AT brianweil developmentoftriiodothyroninepolymericnanoparticlesfortargeteddeliveryinthecardioprotectionagainstischemicinsult AT shakeramousa developmentoftriiodothyroninepolymericnanoparticlesfortargeteddeliveryinthecardioprotectionagainstischemicinsult
_version_	1718412877374685184

Development of Triiodothyronine Polymeric Nanoparticles for Targeted Delivery in the Cardioprotection against Ischemic Insult

Ejemplares similares